comparemela.com

Latest Breaking News On - European commission investment plan for europe - Page 2 : comparemela.com

BioGeneration Ventures BGV IV Fund Closes at €140 Million

BioGeneration Ventures BGV IV Fund Closes at €140 Million

Share: BGV now one of the largest biotech investors in early stage ventures and company creation in Europe BGV IV includes new investors Eli Lilly and Company and Novo Holdings, joining existing investors Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq Four investments already made from BGV IV, with focus on entrepreneurial, therapeutic innovation BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of BGV IV at €140 million ($170 million). BGV IV was oversubscribed, with strong investor demand in the fund. At the final close, LPs included the global pharma company, Eli Lilly and Company, and Novo Holdings (led by its venture arm, Novo Ventures), a world-leading life science investor. They joined other corporate and institutional investors including Bristol Myers Squibb, Schroder Adveq, Industriens Pension, KfW Capital and the European Investment Fund (with the support of the Europ

Novo Holdings participates in BioGeneration Ventures IV Fund

Share: COPENHAGEN, Denmark, Jan. 7, 2021 /PRNewswire/  Novo Ventures, the ventures arm of Novo Holdings, today announces its participation in the BioGeneration Ventures (BGV) oversubscribed fourth fund, BGV IV , which has closed at EUR 140M ($170 million).  As one of the most active biotech investors in US and Europe, Novo Ventures investment strategy is to identify and invest in life science companies developing innovative products with the potential to significantly advance patient care. This investment in BGV IV Fund enhances Novo Ventures reach into BGV s home market, the Benelux, which is fast becoming one of the leading and most productive life sciences regions in Europe. 

A lifeline for Baltic SMEs - Emerging Europe

A lifeline for Baltic SMEs December 17, 2020 Up to 660 million euros of new lending is set to be made available to the SMEs in the Baltic states thanks to a deal between the EIB Group and local financial services provider Luminor. The EIB Group, consisting of the European Investment Bank (EIB) and the European Investment Fund (EIF), has issued a guarantee to financial services provider Luminor to support new lending to companies based in the Baltic states, Estonia, Latvia and Lithuania. The facility is meant to help mitigate the impact of Covid-19 on the Baltic economies. Through a synthetic securitisation transaction – the first of its kind in the Baltics – between Luminor and the EIB Group (with support from the Investment Plan for Europe), Luminor will provide additional lending to small and medium-sized enterprises (SMEs) and Mid-Caps in these difficult economic conditions.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.